Granted Patent B2

US 9,650,446 · App. 14/205,248 · Granted May 16, 2017

Inventors: Gregory Moore (Arcadia, CA); Matthew Bernett (Monrovia, CA); Rumana Rashid (Arcadia, CA); John Desjarlais (Pasadena, CA)

Assignee: Xencor, Inc.

C07K16/468C07K16/2803C07K16/2809C07K16/2896C07K2316/52C07K2317/31C07K2317/51C07K2317/515C07K2317/52C07K2317/528C07K2317/55C07K2317/565C07K2317/622C07K2317/64C07K2317/94

Abstract

Claims (17)

1. A heterodimeric antibody comprising:

a) a first heavy chain comprising:

i) a first variant Fc domain; and

ii) a single chain Fv region (scFv) that binds a first antigen, wherein said scFv region comprises a first variable heavy chain, a variable light chain and a charged scFv linker, wherein said charged scFv linker covalently attaches said first variable heavy chain and said variable light chain; and

b) a second heavy chain comprising a VH-CH1-hinge-CH2-CH3 monomer, wherein VH is a second variable heavy chain and CH2-CH3 is a second variant Fc domain; and

c) a light chain;

wherein said second variant Fc domain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D,

wherein said first and second variant Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K; and

wherein said first variant Fc domain comprises amino acid substitutions S364K/E357Q and second variant Fc domain comprises amino acid substitutions L368D/K370S, wherein numbering is according to the EU index as in Kabat.

2. The heterodimeric antibody of claim 1 , wherein the charged linker is a positive charged linker.

3. The heterodimeric antibody of claim 1 , wherein the charged linker has the amino acid sequence SEQ ID NO: 450.

4. The heterodimeric antibody of claim 1 , wherein said first and second variant Fc domains are selected from the group consisting of variant human IgG1, IgG2 and IgG4 variant Fc domains.

5. The heterodimeric antibody of claim 2 , wherein said first and second variant Fc domains are selected from the group consisting of variant human IgG1, IgG2 and IgG4 variant Fc domains.

6. The heterodimeric antibody of claim 3 , wherein said first and second variant Fc domains are selected from the group consisting of variant human IgG1, IgG2 and IgG4 variant Fc domains.

7. The heterodimeric antibody of claim 1 wherein said first and second variant Fc domains are variant human IgG1 Fc domains.

8. The heterodimeric antibody of claim 2 wherein said first and second variant Fc domains are variant human IgG1 Fc domains.

9. The heterodimeric antibody of claim 3 wherein said first and second variant Fc domains are variant human IgG1 Fc domains.

Assignments (1)

Continuity (10)